• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.

作者信息

Krammer Florian, Srivastava Komal, Alshammary Hala, Amoako Angela A, Awawda Mahmoud H, Beach Katherine F, Bermúdez-González Maria C, Bielak Dominika A, Carreño Juan M, Chernet Rachel L, Eaker Lily Q, Ferreri Emily D, Floda Daniel L, Gleason Charles R, Hamburger Joshua Z, Jiang Kaijun, Kleiner Giulio, Jurczyszak Denise, Matthews Julia C, Mendez Wanni A, Nabeel Ismail, Mulder Lubbertus C F, Raskin Ariel J, Russo Kayla T, Salimbangon Ashley-Beathrese T, Saksena Miti, Shin Amber S, Singh Gagandeep, Sominsky Levy A, Stadlbauer Daniel, Wajnberg Ania, Simon Viviana

机构信息

Icahn School of Medicine at Mount Sinai, New York, NY

出版信息

N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.

DOI:10.1056/NEJMc2101667
PMID:33691060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8008743/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9706/8008743/eb8d7cc7df40/NEJMc2101667_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9706/8008743/eb8d7cc7df40/NEJMc2101667_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9706/8008743/eb8d7cc7df40/NEJMc2101667_f1.jpg

相似文献

1
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗接种后血清阳性者的抗体反应。
N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.
2
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗后的抗体反应。
N Engl J Med. 2021 May 20;384(20):1959-1961. doi: 10.1056/NEJMc2102051. Epub 2021 Mar 23.
3
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
4
SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.两剂科兴疫苗接种方案后接种第三剂科兴疫苗或BNT162b2疫苗后的新冠病毒特异性抗体反应。
J Med Virol. 2022 Jan;94(1):39-41. doi: 10.1002/jmv.27350. Epub 2021 Sep 21.
5
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.评估新冠疫苗需要标准化的中和抗体检测。
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
6
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.既往自然感染人群中新型冠状病毒2型（SARS-CoV-2）的抗体反应
N Engl J Med. 2021 Jul 1;385(1):90-92. doi: 10.1056/NEJMc2103825. Epub 2021 Apr 14.
7
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.接种灭活疫苗后 160 天内血清抗 SARS-CoV-2 抗体的反应和持续时间。
Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554. eCollection 2021.
8
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.mRNA-1273 新冠病毒疫苗在血液透析患者中的安全性和免疫原性。
Front Immunol. 2021 Jun 16;12:704773. doi: 10.3389/fimmu.2021.704773. eCollection 2021.
9
Neutralizing SARS-CoV-2.中和 SARS-CoV-2
Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.
10
Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.一种灭活的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒疫苗诱导的中和抗体的分子去卷积分析
Protein Cell. 2021 Oct;12(10):818-823. doi: 10.1007/s13238-021-00840-z. Epub 2021 Apr 28.

引用本文的文献

1
SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures.自然感染和疫苗接种诱导暴露人群中的SARS-CoV-2抗体及中和动力学。
PLoS One. 2025 Sep 3;20(9):e0331212. doi: 10.1371/journal.pone.0331212. eCollection 2025.
2
Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort.在一个住院队列中，2型免疫反应与症状较轻的新冠肺炎相关。
J Allergy Clin Immunol Glob. 2025 Jun 12;4(4):100515. doi: 10.1016/j.jacig.2025.100515. eCollection 2025 Nov.
3
SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023.

本文引用的文献

1
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
3
Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City.在纽约市对 SARS-CoV-2 进行重复横断面血清监测。
2020年至2023年挪威队列中的新冠病毒特异性体液免疫
BMC Med. 2025 Jun 3;23(1):332. doi: 10.1186/s12916-025-04171-2.
4
Ionizable lipid nanoparticles with functionalized PEG-lipids increase retention in the tumor microenvironment.具有功能化聚乙二醇脂质的可电离脂质纳米颗粒可增加在肿瘤微环境中的滞留时间。
Mol Ther Methods Clin Dev. 2025 Mar 27;33(2):101457. doi: 10.1016/j.omtm.2025.101457. eCollection 2025 Jun 12.
5
Lifestyle and Biochemical Parameters That May Hamper Immune Responses in Pediatric Patients After Immunization with the BNT162b2 mRNA COVID-19 Vaccine.可能妨碍儿科患者接种BNT162b2 mRNA新冠疫苗后免疫反应的生活方式和生化参数
Diseases. 2025 Mar 10;13(3):78. doi: 10.3390/diseases13030078.
6
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).住院康复的新冠病毒肺炎患者的严重急性呼吸综合征冠状病毒2疫苗接种策略：一项随机临床试验（VATICO试验）
Sci Rep. 2025 Mar 22;15(1):9882. doi: 10.1038/s41598-025-92742-x.
7
Early Immune Cell and Antibody Kinetics Following SARS-CoV-2 Vaccination in Healthy Adults and Low-Count Monoclonal B-Cell Lymphocytosis.健康成年人接种新型冠状病毒2疫苗及低计数单克隆B细胞淋巴细胞增多症后的早期免疫细胞和抗体动力学
Int J Mol Sci. 2025 Jan 15;26(2):681. doi: 10.3390/ijms26020681.
8
Current update on the neurological manifestations of long COVID: more questions than answers.新冠长期症状的神经学表现的最新情况：问题多于答案。
EXCLI J. 2024 Nov 27;23:1463-1486. doi: 10.17179/excli2024-7885. eCollection 2024.
9
Dynamic Changes and Trends of SARS-CoV-2 Antibodies Induced by Infection and Vaccination Across Multiple Time Points.感染和接种疫苗后多个时间点诱导产生的SARS-CoV-2抗体的动态变化及趋势
J Med Virol. 2025 Jan;97(1):e70161. doi: 10.1002/jmv.70161.
10
Measures of Population Immunity Can Predict the Dominant Clade of Influenza A (H3N2) in the 2017-2018 Season and Reveal Age-Associated Differences in Susceptibility and Antibody-Binding Specificity.人群免疫水平可预测 2017-2018 年季节甲型流感（H3N2）的优势株，并揭示年龄相关的易感性和抗体结合特异性差异。
Influenza Other Respir Viruses. 2024 Nov;18(11):e70033. doi: 10.1111/irv.70033.
Nature. 2021 Feb;590(7844):146-150. doi: 10.1038/s41586-020-2912-6. Epub 2020 Nov 3.
4
SARS-CoV-2 vaccines in development.正在研发中的 SARS-CoV-2 疫苗。
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
5
SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup.人类中的新型冠状病毒2型血清转化：血清学检测、抗原生产及试验设置的详细方案
Curr Protoc Microbiol. 2020 Jun;57(1):e100. doi: 10.1002/cpmc.100.